Grapiprant is under clinical development by Arrys Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Grapiprant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Grapiprant (RQ-0000007, RQ-7, MR10A7) is under development for the treatment of hepatocellular carcinoma, triple negative/inflammatory breast cancer, non small cell lung cancer, cancer pain, osteoarthritis pain,metastatic colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, chronic pain, osteoarthritis pain, post-operative pain, tumors including liver cancer, colorectal cancer, breast cancer, non-small cell lung cancer adenocarcinoma and gastroenterological cancer, autoimmune disorders and allergies. It is administered intravenously and orally. RQ-0000007 (MR10A7) acts by targeting EP4 receptor.
It was also under development for the treatment of non-small cell lung cancer.
For a complete picture of Grapiprant’s drug-specific PTSR and LoA scores, buy the report here.